Non-small cell lung cancer stage III
Not yet recruitingPhase 3 Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer After Chemoradiation
Phase 3 Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer After Chemoradiation
- Disease:Non-small cell lung cancer stage III
- Substances:DurvalumabIvonescimab
France- Participants:18–64 years · 65+ years
- Substances:Durvalumab
- Sponsor:Summit Therapeutics Inc.









